vs
Kontoor Brands, Inc.（KTB）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Kontoor Brands, Inc.的季度营收约是Revvity的1.1倍（$853.2M vs $772.1M），Revvity净利率更高（12.7% vs 4.3%，领先8.4%），Kontoor Brands, Inc.同比增速更快（27.3% vs 5.9%），Revvity自由现金流更多（$161.8M vs $55.8M），过去两年Kontoor Brands, Inc.的营收复合增速更高（14.2% vs 9.0%）
Kontoor Brands是美国知名服装企业，2019年5月从威富集团分拆独立运营，旗下拥有Lee、Wrangler、Helly Hansen等国际知名服饰品牌，面向全球市场销售各类服饰产品，在休闲服饰及户外功能服饰领域拥有广泛的消费者基础。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
KTB vs RVTY — 直观对比
营收规模更大
KTB
是对方的1.1倍
$772.1M
营收增速更快
KTB
高出21.5%
5.9%
净利率更高
RVTY
高出8.4%
4.3%
自由现金流更多
RVTY
多$106.0M
$55.8M
两年增速更快
KTB
近两年复合增速
9.0%
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $853.2M | $772.1M |
| 净利润 | $36.9M | $98.4M |
| 毛利率 | 41.3% | — |
| 营业利润率 | 7.5% | 14.5% |
| 净利率 | 4.3% | 12.7% |
| 营收同比 | 27.3% | 5.9% |
| 净利润同比 | -47.6% | 3.9% |
| 每股收益（稀释后） | $0.66 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收KTBRVTY
| Q4 25 | — | $772.1M | ||
| Q3 25 | $853.2M | $698.9M | ||
| Q2 25 | $658.3M | $720.3M | ||
| Q1 25 | $622.9M | $664.8M | ||
| Q4 24 | $699.3M | $729.4M | ||
| Q3 24 | $670.2M | $684.0M | ||
| Q2 24 | $606.9M | $691.7M | ||
| Q1 24 | $631.2M | $649.9M |
净利润KTBRVTY
| Q4 25 | — | $98.4M | ||
| Q3 25 | $36.9M | $46.7M | ||
| Q2 25 | $73.9M | $53.9M | ||
| Q1 25 | $42.9M | $42.2M | ||
| Q4 24 | $64.0M | $94.6M | ||
| Q3 24 | $70.5M | $94.4M | ||
| Q2 24 | $51.8M | $55.4M | ||
| Q1 24 | $59.5M | $26.0M |
毛利率KTBRVTY
| Q4 25 | — | — | ||
| Q3 25 | 41.3% | 53.6% | ||
| Q2 25 | 46.3% | 54.5% | ||
| Q1 25 | 47.5% | 56.5% | ||
| Q4 24 | 43.7% | — | ||
| Q3 24 | 44.7% | 56.3% | ||
| Q2 24 | 44.7% | 55.7% | ||
| Q1 24 | 45.2% | 54.6% |
营业利润率KTBRVTY
| Q4 25 | — | 14.5% | ||
| Q3 25 | 7.5% | 11.7% | ||
| Q2 25 | 11.9% | 12.6% | ||
| Q1 25 | 11.8% | 10.9% | ||
| Q4 24 | 12.1% | 16.3% | ||
| Q3 24 | 14.7% | 14.3% | ||
| Q2 24 | 12.4% | 12.4% | ||
| Q1 24 | 13.4% | 6.8% |
净利率KTBRVTY
| Q4 25 | — | 12.7% | ||
| Q3 25 | 4.3% | 6.7% | ||
| Q2 25 | 11.2% | 7.5% | ||
| Q1 25 | 6.9% | 6.4% | ||
| Q4 24 | 9.1% | 13.0% | ||
| Q3 24 | 10.5% | 13.8% | ||
| Q2 24 | 8.5% | 8.0% | ||
| Q1 24 | 9.4% | 4.0% |
每股收益（稀释后）KTBRVTY
| Q4 25 | — | $0.86 | ||
| Q3 25 | $0.66 | $0.40 | ||
| Q2 25 | $1.32 | $0.46 | ||
| Q1 25 | $0.76 | $0.35 | ||
| Q4 24 | $1.13 | $0.77 | ||
| Q3 24 | $1.26 | $0.77 | ||
| Q2 24 | $0.92 | $0.45 | ||
| Q1 24 | $1.05 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $82.4M | $919.9M |
| 总债务越低越好 | $1.3B | — |
| 股东权益账面价值 | $529.6M | $7.3B |
| 总资产 | $2.9B | $12.2B |
| 负债/权益比越低杠杆越低 | 2.53× | — |
8季度趋势，按日历期对齐
现金及短期投资KTBRVTY
| Q4 25 | — | $919.9M | ||
| Q3 25 | $82.4M | $931.4M | ||
| Q2 25 | $107.5M | $991.8M | ||
| Q1 25 | $356.7M | $1.1B | ||
| Q4 24 | $334.1M | $1.2B | ||
| Q3 24 | $269.4M | $1.2B | ||
| Q2 24 | $224.3M | $2.0B | ||
| Q1 24 | $215.1M | $1.7B |
总债务KTBRVTY
| Q4 25 | — | — | ||
| Q3 25 | $1.3B | — | ||
| Q2 25 | $1.4B | — | ||
| Q1 25 | $735.6M | — | ||
| Q4 24 | $740.3M | — | ||
| Q3 24 | $745.0M | — | ||
| Q2 24 | $749.7M | — | ||
| Q1 24 | $779.2M | — |
股东权益KTBRVTY
| Q4 25 | — | $7.3B | ||
| Q3 25 | $529.6M | $7.4B | ||
| Q2 25 | $498.3M | $7.6B | ||
| Q1 25 | $426.7M | $7.6B | ||
| Q4 24 | $400.1M | $7.7B | ||
| Q3 24 | $356.9M | $7.9B | ||
| Q2 24 | $367.2M | $7.9B | ||
| Q1 24 | $387.2M | $7.8B |
总资产KTBRVTY
| Q4 25 | — | $12.2B | ||
| Q3 25 | $2.9B | $12.1B | ||
| Q2 25 | $2.7B | $12.4B | ||
| Q1 25 | $1.7B | $12.4B | ||
| Q4 24 | $1.7B | $12.4B | ||
| Q3 24 | $1.7B | $12.8B | ||
| Q2 24 | $1.6B | $13.4B | ||
| Q1 24 | $1.7B | $13.4B |
负债/权益比KTBRVTY
| Q4 25 | — | — | ||
| Q3 25 | 2.53× | — | ||
| Q2 25 | 2.74× | — | ||
| Q1 25 | 1.72× | — | ||
| Q4 24 | 1.85× | — | ||
| Q3 24 | 2.09× | — | ||
| Q2 24 | 2.04× | — | ||
| Q1 24 | 2.01× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $64.1M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $55.8M | $161.8M |
| 自由现金流率自由现金流/营收 | 6.5% | 21.0% |
| 资本支出强度资本支出/营收 | 1.0% | 2.6% |
| 现金转化率经营现金流/净利润 | 1.74× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $228.0M | $509.4M |
8季度趋势，按日历期对齐
经营现金流KTBRVTY
| Q4 25 | — | $182.0M | ||
| Q3 25 | $64.1M | $138.5M | ||
| Q2 25 | $25.7M | $134.3M | ||
| Q1 25 | $77.6M | $128.2M | ||
| Q4 24 | $82.0M | $174.2M | ||
| Q3 24 | $133.6M | $147.9M | ||
| Q2 24 | $96.2M | $158.6M | ||
| Q1 24 | $56.5M | $147.6M |
自由现金流KTBRVTY
| Q4 25 | — | $161.8M | ||
| Q3 25 | $55.8M | $120.0M | ||
| Q2 25 | $22.4M | $115.5M | ||
| Q1 25 | $74.9M | $112.2M | ||
| Q4 24 | $75.0M | $149.8M | ||
| Q3 24 | $129.9M | $125.6M | ||
| Q2 24 | $92.6M | $136.6M | ||
| Q1 24 | $52.0M | $129.7M |
自由现金流率KTBRVTY
| Q4 25 | — | 21.0% | ||
| Q3 25 | 6.5% | 17.2% | ||
| Q2 25 | 3.4% | 16.0% | ||
| Q1 25 | 12.0% | 16.9% | ||
| Q4 24 | 10.7% | 20.5% | ||
| Q3 24 | 19.4% | 18.4% | ||
| Q2 24 | 15.3% | 19.7% | ||
| Q1 24 | 8.2% | 20.0% |
资本支出强度KTBRVTY
| Q4 25 | — | 2.6% | ||
| Q3 25 | 1.0% | 2.6% | ||
| Q2 25 | 0.5% | 2.6% | ||
| Q1 25 | 0.4% | 2.4% | ||
| Q4 24 | 1.0% | 3.4% | ||
| Q3 24 | 0.6% | 3.3% | ||
| Q2 24 | 0.6% | 3.2% | ||
| Q1 24 | 0.7% | 2.7% |
现金转化率KTBRVTY
| Q4 25 | — | 1.85× | ||
| Q3 25 | 1.74× | 2.97× | ||
| Q2 25 | 0.35× | 2.49× | ||
| Q1 25 | 1.81× | 3.03× | ||
| Q4 24 | 1.28× | 1.84× | ||
| Q3 24 | 1.89× | 1.57× | ||
| Q2 24 | 1.86× | 2.87× | ||
| Q1 24 | 0.95× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
KTB
| International Member | $292.0M | 34% |
| CTC Triangle B.V | $192.7M | 23% |
| Lee Segment | $186.7M | 22% |
| Helly Hansen Segment | $185.9M | 22% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
